{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:21:44Z","timestamp":1767140504943,"version":"build-2238731810"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100008091","name":"Golestan University of Medical Sciences","doi-asserted-by":"publisher","award":["et- 157495"],"award-info":[{"award-number":["et- 157495"]}],"id":[{"id":"10.13039\/501100008091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00705-016-3091-5","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T08:40:58Z","timestamp":1475484058000},"page":"333-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Synergistic effect of programmed cell death protein\u00a01 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine"],"prefix":"10.1007","volume":"162","author":[{"given":"Soheila","family":"Moeini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Saeidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Fotouhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdieh","family":"Mondanizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadegh","family":"Shirian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Mohebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Gorji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Ghaemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"key":"3091_CR1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jviromet.2014.05.013","volume":"206","author":"AA Bahrami","year":"2014","unstructured":"Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H (2014) DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice. J Virol Methods 206:12\u201318","journal-title":"J Virol Methods"},{"key":"3091_CR2","first-page":"444","volume":"1","author":"ID Bobanga","year":"2013","unstructured":"Bobanga ID, Petrosiute A, Huang AY (2013) Chemokines as cancer vaccine adjuvants. Vaccines 1:444\u2013462","journal-title":"Chemokines as cancer vaccine adjuvants. Vaccines"},{"key":"3091_CR3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4161\/onci.21285","volume":"1","author":"R Bos","year":"2012","unstructured":"Bos R, Marquardt KL, Cheung J, Sherman LA (2012) Functional differences between low-and high-affinity CD8+ T cells in the tumor environment. Oncoimmunology 1:1239\u20131247","journal-title":"Oncoimmunology"},{"key":"3091_CR4","doi-asserted-by":"crossref","unstructured":"Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I (2016) Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer immunology, immunotherapy : CII","DOI":"10.1007\/s00262-016-1831-8"},{"key":"3091_CR5","doi-asserted-by":"crossref","first-page":"10680","DOI":"10.1128\/JVI.01747-15","volume":"89","author":"AA Chen","year":"2015","unstructured":"Chen AA, Gheit T, Franceschi S, Tommasino M, Clifford GM (2015) Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide. J Virol 89:10680\u201310687","journal-title":"J Virol"},{"key":"3091_CR6","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceed Nat Acad Sci USA 107:4275\u20134280","journal-title":"Proceed Nat Acad Sci USA"},{"key":"3091_CR7","doi-asserted-by":"crossref","unstructured":"Drake C (2012) Combination immunotherapy approaches. Ann Oncol 23:viii41\u2013viii46","DOI":"10.1093\/annonc\/mds262"},{"key":"3091_CR8","doi-asserted-by":"crossref","unstructured":"Dubinett SM, Lee JM, Sharma S, Mule JJ (2010) Chemokines: can effector cells be redirected to the site of the tumor? Cancer journal (Sudbury, Mass) 16:325-335","DOI":"10.1097\/PPO.0b013e3181eb33bc"},{"key":"3091_CR9","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73:3591\u20133603","journal-title":"Cancer Res"},{"key":"3091_CR10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2004-06-2156","volume":"105","author":"JW Friedberg","year":"2005","unstructured":"Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS (2005) Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-\u03b1\/\u03b2\u2013inducible gene expression, without significant toxicity. Blood 105:489\u2013495","journal-title":"Blood"},{"key":"3091_CR11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12929-016-0238-3","volume":"23","author":"F Gableh","year":"2016","unstructured":"Gableh F, Saeidi M, Hemati S, Hamdi K, Soleimanjahi H, Gorji A, Ghaemi A (2016) Combination of the toll like receptor agonist and alpha-Galactosylceramide as an efficient adjuvant for cancer vaccine. J Biomed Sci 23:16","journal-title":"J Biomed Sci"},{"key":"3091_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cimid.2007.01.002","volume":"30","author":"A Ghaemi","year":"2007","unstructured":"Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, Ebtekar M (2007) Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB\/c mice. Comp Immunol Microbiol Infect Dis 30:197\u2013210","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"3091_CR13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000320197","volume":"54","author":"A Ghaemi","year":"2011","unstructured":"Ghaemi A, Soleimanjahi H, Gill P, Hassan ZM, Razeghi S, Fazeli M, Razavinikoo SM (2011) Protection of mice by a lambda-based therapeutic vaccine against cancer associated with human papillomavirus type 16. Intervirology 54:105\u2013112","journal-title":"Intervirology"},{"key":"3091_CR14","doi-asserted-by":"crossref","unstructured":"He J, Hu Y, Hu M, Li B (2015) Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 5","DOI":"10.1038\/srep13110"},{"key":"3091_CR15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/sji.12145","volume":"79","author":"C Hong","year":"2014","unstructured":"Hong C, Lee HJ, Kim HJ, Lee JJ (2014) The Lymphoid Chemokine CCL21 Enhances the Cytotoxic T Lymphocyte-Inducing Functions of Dendritic Cells. Scand J Immunol 79:173\u2013180","journal-title":"Scand J Immunol"},{"key":"3091_CR16","doi-asserted-by":"crossref","unstructured":"Huang Z, Peng S, Knoff J, Lee SY, Yang B, Wu TC, Hung CF (2015) Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model. J Biomed Sci 22","DOI":"10.1186\/s12929-014-0111-1"},{"key":"3091_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-014-0365-0","volume":"13","author":"M Ji","year":"2015","unstructured":"Ji M, Liu Y, Li Q, Li X-D, Zhao W-Q, Zhang H, Zhang X, Jiang J-T, Wu C-P (2015) PD-1\/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of translational medicine 13:1","journal-title":"Journal of translational medicine"},{"key":"3091_CR18","doi-asserted-by":"crossref","unstructured":"Jin H-T, Ahmed R, Okazaki T (2010) Role of PD-1 in regulating T-cell immunity. Negative Co-Receptors and Ligands. Springer, pp 17\u201337","DOI":"10.1007\/82_2010_116"},{"key":"3091_CR19","first-page":"2062","volume":"61","author":"CJ Kirk","year":"2001","unstructured":"Kirk CJ, Hartigan-O\u2019Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L, Mule JJ (2001) T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61:2062\u20132070","journal-title":"Cancer Res"},{"key":"3091_CR20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.febslet.2013.10.015","volume":"588","author":"C Kyi","year":"2014","unstructured":"Kyi C, Postow MA (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588:368\u2013376","journal-title":"FEBS Lett"},{"key":"3091_CR21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12026-009-8141-6","volume":"47","author":"K Lin","year":"2010","unstructured":"Lin K, Roosinovich E, Ma B, Hung CF, Wu TC (2010) Therapeutic HPV DNA vaccines. Immunol Res 47:86\u2013112","journal-title":"Immunol Res"},{"key":"3091_CR22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1479-5876-12-36","volume":"12","author":"L Lu","year":"2014","unstructured":"Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X (2014) Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Trans Med 12:36","journal-title":"J Trans Med"},{"key":"3091_CR23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/157339410791202583","volume":"6","author":"B Ma","year":"2010","unstructured":"Ma B, Xu Y, Hung C-F, Wu T-C (2010) HPV and therapeutic vaccines: where are we in 2010? Curr Cancer Therapy Rev 6:81\u2013103","journal-title":"Curr Cancer Therapy Rev"},{"key":"3091_CR24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4161\/onci.19534","volume":"1","author":"AJ McGray","year":"2012","unstructured":"McGray AJ, Bernard D, Hallett R, Kelly R, Jha M, Gregory C, Bassett JD, Hassell JA, Pare G, Wan Y, Bramson JL (2012) Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology 1:419\u2013431","journal-title":"Oncoimmunology"},{"key":"3091_CR25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coi.2014.12.009","volume":"34","author":"SK Mittal","year":"2015","unstructured":"Mittal SK, Roche PA (2015) Suppression of antigen presentation by IL-10. Curr Opin Immunol 34:22\u201327","journal-title":"Curr Opin Immunol"},{"key":"3091_CR26","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1002\/eji.201141639","volume":"41","author":"M Mkrtichyan","year":"2011","unstructured":"Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN (2011) Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Euro J Immunol 41:2977\u20132986","journal-title":"Euro J Immunol"},{"key":"3091_CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pharmthera.2015.07.001","volume":"154","author":"D M\u00fcller","year":"2015","unstructured":"M\u00fcller D (2015) Antibody fusions with immunomodulatory proteins for cancer therapy. Pharmacol Ther 154:57\u201366","journal-title":"Pharmacol Ther"},{"key":"3091_CR28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12250-013-3291-z","volume":"28","author":"M Naderi","year":"2013","unstructured":"Naderi M, Saeedi A, Moradi A, Kleshadi M, Zolfaghari MR, Gorji A, Ghaemi A (2013) Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virologica Sinica 28:167\u2013173","journal-title":"Virologica Sinica"},{"key":"3091_CR29","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1158\/1078-0432.CCR-13-2781","volume":"20","author":"T Nagato","year":"2014","unstructured":"Nagato T, Lee YR, Harabuchi Y, Celis E (2014) Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res Off J Am Assoc Cancer Res 20:1223\u20131234","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3091_CR30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/cgt.2011.69","volume":"19","author":"T Nguyen-Hoai","year":"2012","unstructured":"Nguyen-Hoai T, Baldenhofer G, Sayed Ahmed MS, Pham-Duc M, Vu MD, Lipp M, Dorken B, Pezzutto A, Westermann J (2012) CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2\/neu mouse tumor model. Cancer Gene Therapy 19:69\u201376","journal-title":"Cancer Gene Therapy"},{"key":"3091_CR31","doi-asserted-by":"crossref","unstructured":"Nguyen-Hoai T, Pham-Duc M, Gries M, D\u00f6rken B, Pezzutto A, Westermann J (2016) CCL4 as an adjuvant for DNA vaccination in a Her2\/neu mouse tumor model. Cancer Gene Therapy","DOI":"10.1038\/cgt.2016.9"},{"key":"3091_CR32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clim.2014.04.010","volume":"153","author":"A Pedoeem","year":"2014","unstructured":"Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A (2014) Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 153:145\u2013152","journal-title":"Clin Immunol"},{"key":"3091_CR33","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/2326-6066.CIR-14-0206","volume":"3","author":"BT Rekoske","year":"2015","unstructured":"Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG (2015) PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res 3:946\u2013955","journal-title":"Cancer Immunol Res"},{"key":"3091_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-2-35","volume":"2","author":"K Riedl","year":"2003","unstructured":"Riedl K, Baratelli F, Batra RK, Yang S, Luo J, Escuadro B, Figlin R, Strieter R, Sharma S, Dubinett S (2003) Overexpression of CCL-21\/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer 2:1","journal-title":"Mol Cancer"},{"key":"3091_CR35","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-09-0280","volume":"8","author":"CL Roland","year":"2009","unstructured":"Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA (2009) Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 8:1761\u20131771","journal-title":"Mol Cancer Ther"},{"key":"3091_CR36","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.5306\/wjco.v5.i5.1002","volume":"5","author":"R Rosales","year":"2014","unstructured":"Rosales R, Rosales C (2014) Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol 5:1002","journal-title":"World J Clin Oncol"},{"key":"3091_CR37","doi-asserted-by":"crossref","first-page":"656340","DOI":"10.1155\/2012\/656340","volume":"2012","author":"EN Rozali","year":"2012","unstructured":"Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ (2012) Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012:656340","journal-title":"Clin Dev Immunol"},{"key":"3091_CR38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/erv.11.188","volume":"11","author":"F Saade","year":"2012","unstructured":"Saade F, Petrovsky N (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 11:189\u2013209","journal-title":"Expert Rev Vaccines"},{"key":"3091_CR39","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00705-014-2024-4","volume":"159","author":"A Sajadian","year":"2014","unstructured":"Sajadian A, Tabarraei A, Soleimanjahi H, Fotouhi F, Gorji A, Ghaemi A (2014) Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol 159:1951\u20131960","journal-title":"Arch Virol"},{"key":"3091_CR40","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187\u20132194","journal-title":"J Exp Med"},{"key":"3091_CR41","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.gt.3302772","volume":"13","author":"V Schmitz","year":"2006","unstructured":"Schmitz V, Vilanueva H, Raskopf E, Hilbert T, Barajas M, Dzienisowicz C, Gorschl\u00fcter M, Strehl J, Rabe C, Sauerbruch T (2006) Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice. Gene Therapy 13:1198\u20131205","journal-title":"Gene Therapy"},{"key":"3091_CR42","doi-asserted-by":"crossref","unstructured":"Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol (Baltimore, Md : 1950) 164:4558\u20134563","DOI":"10.4049\/jimmunol.164.9.4558"},{"key":"3091_CR43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5732\/cjc.014.10122","volume":"33","author":"E Sharon","year":"2014","unstructured":"Sharon E, Streicher H, Goncalves P, Chen HX (2014) Immune checkpoints in cancer clinical trials. Chinese Journal of Cancer 33:434\u2013444","journal-title":"Chinese Journal of Cancer"},{"key":"3091_CR44","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-8722-6-74","volume":"6","author":"L Shi","year":"2013","unstructured":"Shi L, Chen S, Yang L, Li Y (2013) The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 6:74","journal-title":"J Hematol Oncol"},{"key":"3091_CR45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12929-014-0069-z","volume":"21","author":"A Tahamtan","year":"2014","unstructured":"Tahamtan A, Ghaemi A, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, Moradi A, Atyabi F, Kelishadi M (2014) Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems. J Biomed Sci 21:69","journal-title":"J Biomed Sci"},{"key":"3091_CR46","first-page":"6545","volume":"62","author":"KA Tolba","year":"2002","unstructured":"Tolba KA, Bowers WJ, Muller J, Housekneckt V, Giuliano RE, Federoff HJ, Rosenblatt JD (2002) Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res 62:6545\u20136551","journal-title":"Cancer Res"},{"key":"3091_CR47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nature Rev Cancer 12:237\u2013251","journal-title":"Nature Rev Cancer"},{"key":"3091_CR48","doi-asserted-by":"crossref","unstructured":"Vezys V, Penaloza-MacMaster P, Barber DL, Ha SJ, Konieczny B, Freeman GJ, Mittler RS, Ahmed R (2011) 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol (Baltimore, Md : 1950) 187:1634\u20131642","DOI":"10.4049\/jimmunol.1100077"},{"key":"3091_CR49","doi-asserted-by":"crossref","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HS (2015) Immune evasion in cancer: Mechanistic basis and therapeutic strategies. In: Seminars in Cancer Biology. Elsevier, pp S185\u2013S198","DOI":"10.1016\/j.semcancer.2015.03.004"},{"key":"3091_CR50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.med.56.082103.104549","volume":"57","author":"TA Waldmann","year":"2006","unstructured":"Waldmann TA (2006) Effective cancer therapy through immunomodulation. Ann Rev Med 57:65\u201381","journal-title":"Ann Rev Med"},{"key":"3091_CR51","doi-asserted-by":"crossref","unstructured":"Yang MC, Yang A, Qiu J, Yang B, He L, Tsai YC, Jeang J, Wu TC, Hung CF (2016) Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant. Cell Biosci 6","DOI":"10.1186\/s13578-016-0083-9"}],"updated-by":[{"DOI":"10.1007\/s00705-016-3160-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000}}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-016-3091-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-016-3091-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-016-3091-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T02:24:35Z","timestamp":1568427875000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-016-3091-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["3091"],"URL":"https:\/\/doi.org\/10.1007\/s00705-016-3091-5","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]}}}